WilliamGeorgeGoodmanMD

PubMed

• 3 citations
  Activation of the Calcium Receptor by Calcimimetic Agents is Preserved Despite Modest Attenuating Effects of Hyperphosphatemia
  William G. Goodman, Donald T. Ward, Kevin J. Martin, Debra Drayer, Carol Moore, Jiahong Xu, James Lai, Yun Chon, Edward F. Nemeth> ;Journal of the American Society of Nephrology. 2021 Nov 3
• Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism.
  Yu, L.,Tomlinson, J. E.,Alexander, S. T.,Hensley, K.,Han, C. Y.,Dwyer, D.,Stolina, M.,Dean, C.,Goodman, W. G.,Richards, W. G.,Li, X.> ;Calcif. Tissue Int.. 2017 Oct 19
• The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial.
  Chang, T. I.,Abdalla, S.,London, G. M.,Block, G. A.,Correa-Rotter, R.,Drüeke, T. B.,Floege, J.,Herzog, C. A.,Mahaffey, K. W.,Moe, S. M.,Parfrey, P. S.,Wheeler, D. C.,D...> ;J Hum Hypertens. 2015 Jun 05
• Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial.
  Pun, P. H.,Abdalla, S.,Block, G. A.,Chertow, G. M.,Correa-Rotter, R.,Dehmel, B.,Drüeke, T. B.,Floege, J.,Goodman, W. G.,Herzog, C. A.,London, G. M.,Mahaffey, K. W.,Moe...> ;Hemodial Int. 2015 Nov 14
• 2 citations
  Cardiovascular and Renal Outcomes Trials-Is There a Difference?
  Paolo Raggi, Rob J. de Boer, William G. Goodman, Kamyar Kalantar-Zadeh, Glenn M. Chertow, Vasily Belozeroff> ;The American Journal of Cardiology. 2015 Sep 15
• 57 citations
  The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial
  , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,...> ;Clinical Journal of the American Society of Nephrology. 2015 May 7
• The Use of Calcimimetics for the Treatment of Secondary Hyperparathyroidism: A 10 Year Evidence Review.
  Rodríguez, M.,Goodman, W. G.,Liakopoulos, V.,Messa, P.,Wiecek, A.,Cunningham, J.> ;Semin Dial. 2015 Mar 11
• Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitami...
  Chertow, G.M., Lu, Z.J., Xu, X., Knight, T.G., Goodman, W.G., Bushinsky, D.A., Block, G.A.> ;Hemodial Int. 2012 Apr
• The association of vitamin D use with hypercalcemia and hyperphosphatemia in hemodialysis patients: a case-crossover study.
  Kilpatrick, R.D., Danese, M.D., Belozeroff, V., Smirnakis, K., Goodman, W.G., Rothman, K.J.> ;Pharmacoepidemiol Drug Saf. 2011 Sep
• When is Vitamin D Contraindicated in Dialysis Patients?
  Goodman, W.G.> ;Semin Dial. 2009-05-01
• Cinacalcet lowers serum alkaline phosphatase in maintenance hemodialysis patients.
  Belozeroff, V., Goodman, W.G., Ren, L., Kalantar-Zadeh, K.> ;Clin J Am Soc Nephrol. 2009 Mar
• Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE st...
  Fishbane, S., Shapiro, W.B., Corry, D.B., Vicks, S.L., Roppolo, M., Rappaport, K., Ling, X., Goodman, W.G., Turner, S., Charytan, C.> ;Clin J Am Soc Nephrol. 2008-11-01
• 103 citations
  Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics
  William G. Goodman, L.D. Quarles> ;Kidney International. 2008 Aug 1
• Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview.
  Chertow, G.M., Pupim, L.B., Block, G.A., Correa-Rotter, R., Drueke, T.B., Floege, J., Goodman, W.G., London, G.M., Mahaffey, K.W., Moe, S.M., Wheeler, D.C., Albizem, M...> ;Clin J Am Soc Nephrol. 2007 Sep
• Comments on plasma parathyroid hormone levels and their relationship to bone histopathology among patients undergoing dialysis.
  Goodman, W.G.> ;Semin Dial. 2007-01-01
• PTH(1-84)/PTH(7-84): a balance of power.
  Friedman, P.A., Goodman, W.G.> ;Am J Physiol Renal Physiol. 2006 May
• 2 citations
  Renal osteodystrophy for nonnephrologists
  William G. Goodman> ;Journal of Bone and Mineral Metabolism. 2006 Jan 1
• Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry.
  Lehmann, G., Stein, G., Hüller, M., Schemer, R., Ramakrishnan, K., Goodman, W. G.> ;Kidney Int. 2005 Sep
• First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl.
  Martin, K. J., Jüppner, H., Sherrard, D. J., Goodman, W. G., Kaplan, M. R., Nassar, G., Campbell, P., Curzi, M., Charytan, C., McCary, L. C., Guo, M. D., Turner, S. A....> ;Kidney Int. 2005 Sep
• Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vita...
  Salusky, I. B., Goodman, W. G., Sahney, S., Gales, B., Perilloux, A., Wang, H. J., Elashoff, R. M., Jüppner, H.> ;J Am Soc Nephrol. 2005 Aug
• 11 citations
  Calcimimetics: a remedy for all problems of excess parathyroid hormone activity in chronic kidney disease?
  William G. Goodman> ;Current Opinion in Nephrology and Hypertension. 2005 Jul 1
• 17 citations
  The evolution of assays for parathyroid hormone.
  William G. Goodman> ;Seminars in Dialysis. 2005 Jul 1
• 10 citations
  Calcium and Phosphorus Metabolism in Patients Who Have Chronic Kidney Disease
  William G. Goodman> ;The Medical Clinics of North America. 2005 May 1
• Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl.
  Moe, S. M., Chertow, G. M., Coburn, J. W., Quarles, L. D., Goodman, W. G., Block, G. A., Drüeke, T. B., Cunningham, J., Sherrard, D. J., McCary, L. C., Olson, K. A., T...> ;Kidney Int. 2005 Feb
• The flavors of vitamin D: tasting the molecular mechanisms.
  Goodman, W.G.> ;Kidney Int. 2004 Sep
• Join now to see all